JNJ 108.82 Johnson & Johnson $JNJ Hit a 52 week high of 109.26 Closing the day 11/05/14 at 108.82 +0.20 +0.18% With a day low of 107.95 and a total volume of 6,966,795.
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
Final Glance: Pharmaceuticals companies
AP - Wed Nov 05, 5:04PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.82 (+0.20), BAX: 70.90 (+2.45), PFE: 30.04 (-0.24), BMY: 57.82 (-0.02)
Final Glance: Medical Devices companies
AP - Wed Nov 05, 5:04PM CST
NEW YORK (AP) — Shares of some top medical devices companies were up at the close of trading:
ZMH: 110.99 (+1.78), JNJ: 108.82 (+0.20), MDT: 68.70 (+0.77), BAX: 70.90 (+2.45)
Midday Glance: Medical Devices companies
AP - Wed Nov 05, 12:21PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.99 (+1.78), JNJ: 108.82 (+0.20), MDT: 68.70 (+0.77), BAX: 70.90 (+2.45)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 05, 12:21PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.82 (+0.20), BAX: 70.90 (+2.45), PFE: 30.04 (-0.24), BMY: 57.82 (-0.02)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.82 (+0.20), PCYC: 131.03 (+0.03), AZN: 73.47 (+0.11), AMAG: 33.78 (-0.32)
Early Glance: Pharmaceuticals companies
AP - Wed Nov 05, 9:52AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.82 (+0.20), BAX: 70.90 (+2.45), PFE: 30.04 (-0.24), BMY: 57.82 (-0.02)
Early Glance: Medical Devices companies
AP - Wed Nov 05, 9:52AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.99 (+1.78), JNJ: 108.82 (+0.20), MDT: 68.70 (+0.77), BAX: 70.90 (+2.45)
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50
ACCESSWIRE - Wed Nov 05, 8:26AM CST
900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA
JNJ: 108.82 (+0.20)
Johnson & Johnson Considering Settlement of $250 Million to Close More Than 1,000 DePuy ASR Metal-on-Metal Hip Device Claims, Parker Waichman LLP Comments.
PRWeb - Wed Nov 05, 8:07AM CST
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that healthcare giant, Johnson & Johnson, may settle for more than $250 million to resolve lawsuits that were brought over its DePuy Orthopaedics unit's ASR (articular surface replacements) metal-on-metal hip implant devices. The potential settlement involves cases that were not included in a 2013 settlement of $2.5 billion that involved similar device failure claims, according to an October 13, 2014 Bloomberg News report. The consolidated federal case is: In re DePuy Orthopedics Inc., ASR Hip Implant Products Liability Litigation, 10-MD-2197, U.S. District Court, Northern District of Ohio (Toledo).
JNJ: 108.82 (+0.20)
After Yesterday's Rally of 1.08% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:42PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $107.34 to a high of $108.73. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.18 on volume of 9.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 108.82 (+0.20)
Johnson & Johnson Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Tue Nov 04, 3:41PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $107.34 to a high of $108.73. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.18 on volume of 9.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 108.82 (+0.20)
Baron and Budd Investigating Potential Xarelto Lawsuits
Business Wire - Tue Nov 04, 3:01PM CST
The attorneys at the national law firm of Baron and Budd have been investigating potential lawsuits involving the blood thinner Xarelto, a prescription drug distributed in the United States by Johnson & Johnson subsidiary Janssen Pharmaceuticals. Several patients have reported serious health problems after using the drug, including blood clots, strokes, kidney and liver damage, and severe internal bleeding - a sometimes fatal condition.
JNJ: 108.82 (+0.20)
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $108.14
Comtex SmarTrend(R) - Tue Nov 04, 9:00AM CST
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $107.44 and have already reached the first level of resistance at $108.14. Analysts will be watching for a cross of the next upside pivot targets of $108.81 and $110.18.
JNJ: 108.82 (+0.20)
Legal-Bay Lawsuit Settlement Funding Updates News on All Major Hip Litigations
PR Newswire - Tue Nov 04, 4:00AM CST
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Johnson & Johnson won in the first bellwether trial recently in the case against their DePuy Pinnacle system metal-on-metal hip implant device. The plaintiff claimed the design was defective and the company failed to adequately warn the patient of the potential complications, however, J&J proved victorious after a seven week trial. Last year, DePuy settled over 7,000 lawsuits for $2.5 billion over a different hip implant device (the ASR device) which they recalled in 2010, but regarding the Pinnacle lawsuits, they opted to go to trial. DePuy defended their Pinnacle device which they stopped selling in 2013, claiming that it wasn't the defective design of the implant that was the issue, but the incorrect positioning of it into the body by a small number of surgeons. They insist that they had previously warned surgeons that incorrectly positioning the implant into patients' bodies could cause damage tissue and device failure. The jury deliberated for two days, and ultimately rejected the plaintiff's allegations, deciding the plaintiff's injuries were not caused by failure or negligence on DePuy's behalf. The bellwether trial took place in the U.S. District Court for the Northern District of Texas under Judge Ed Kinkeade. There are still 6,500 cases pending relating to the company's Pinnacle hip implant device, and the next trial is scheduled for January.
JNJ: 108.82 (+0.20)
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
Final Glance: Pharmaceuticals companies
AP - Wed Nov 05, 5:04PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.82 (+0.20), BAX: 70.90 (+2.45), PFE: 30.04 (-0.24), BMY: 57.82 (-0.02)
Final Glance: Medical Devices companies
AP - Wed Nov 05, 5:04PM CST
NEW YORK (AP) — Shares of some top medical devices companies were up at the close of trading:
ZMH: 110.99 (+1.78), JNJ: 108.82 (+0.20), MDT: 68.70 (+0.77), BAX: 70.90 (+2.45)
Midday Glance: Medical Devices companies
AP - Wed Nov 05, 12:21PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.99 (+1.78), JNJ: 108.82 (+0.20), MDT: 68.70 (+0.77), BAX: 70.90 (+2.45)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 05, 12:21PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.82 (+0.20), BAX: 70.90 (+2.45), PFE: 30.04 (-0.24), BMY: 57.82 (-0.02)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.82 (+0.20), PCYC: 131.03 (+0.03), AZN: 73.47 (+0.11), AMAG: 33.78 (-0.32)
Early Glance: Pharmaceuticals companies
AP - Wed Nov 05, 9:52AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.82 (+0.20), BAX: 70.90 (+2.45), PFE: 30.04 (-0.24), BMY: 57.82 (-0.02)
Early Glance: Medical Devices companies
AP - Wed Nov 05, 9:52AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.99 (+1.78), JNJ: 108.82 (+0.20), MDT: 68.70 (+0.77), BAX: 70.90 (+2.45)
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50
ACCESSWIRE - Wed Nov 05, 8:26AM CST
900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA
JNJ: 108.82 (+0.20)
Johnson & Johnson Considering Settlement of $250 Million to Close More Than 1,000 DePuy ASR Metal-on-Metal Hip Device Claims, Parker Waichman LLP Comments.
PRWeb - Wed Nov 05, 8:07AM CST
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that healthcare giant, Johnson & Johnson, may settle for more than $250 million to resolve lawsuits that were brought over its DePuy Orthopaedics unit's ASR (articular surface replacements) metal-on-metal hip implant devices. The potential settlement involves cases that were not included in a 2013 settlement of $2.5 billion that involved similar device failure claims, according to an October 13, 2014 Bloomberg News report. The consolidated federal case is: In re DePuy Orthopedics Inc., ASR Hip Implant Products Liability Litigation, 10-MD-2197, U.S. District Court, Northern District of Ohio (Toledo).
JNJ: 108.82 (+0.20)
After Yesterday's Rally of 1.08% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:42PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $107.34 to a high of $108.73. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.18 on volume of 9.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 108.82 (+0.20)
Johnson & Johnson Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Tue Nov 04, 3:41PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $107.34 to a high of $108.73. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.18 on volume of 9.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 108.82 (+0.20)
Baron and Budd Investigating Potential Xarelto Lawsuits
Business Wire - Tue Nov 04, 3:01PM CST
The attorneys at the national law firm of Baron and Budd have been investigating potential lawsuits involving the blood thinner Xarelto, a prescription drug distributed in the United States by Johnson & Johnson subsidiary Janssen Pharmaceuticals. Several patients have reported serious health problems after using the drug, including blood clots, strokes, kidney and liver damage, and severe internal bleeding - a sometimes fatal condition.
JNJ: 108.82 (+0.20)
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $108.14
Comtex SmarTrend(R) - Tue Nov 04, 9:00AM CST
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $107.44 and have already reached the first level of resistance at $108.14. Analysts will be watching for a cross of the next upside pivot targets of $108.81 and $110.18.
JNJ: 108.82 (+0.20)
Legal-Bay Lawsuit Settlement Funding Updates News on All Major Hip Litigations
PR Newswire - Tue Nov 04, 4:00AM CST
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Johnson & Johnson won in the first bellwether trial recently in the case against their DePuy Pinnacle system metal-on-metal hip implant device. The plaintiff claimed the design was defective and the company failed to adequately warn the patient of the potential complications, however, J&J proved victorious after a seven week trial. Last year, DePuy settled over 7,000 lawsuits for $2.5 billion over a different hip implant device (the ASR device) which they recalled in 2010, but regarding the Pinnacle lawsuits, they opted to go to trial. DePuy defended their Pinnacle device which they stopped selling in 2013, claiming that it wasn't the defective design of the implant that was the issue, but the incorrect positioning of it into the body by a small number of surgeons. They insist that they had previously warned surgeons that incorrectly positioning the implant into patients' bodies could cause damage tissue and device failure. The jury deliberated for two days, and ultimately rejected the plaintiff's allegations, deciding the plaintiff's injuries were not caused by failure or negligence on DePuy's behalf. The bellwether trial took place in the U.S. District Court for the Northern District of Texas under Judge Ed Kinkeade. There are still 6,500 cases pending relating to the company's Pinnacle hip implant device, and the next trial is scheduled for January.
JNJ: 108.82 (+0.20)
